TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: A 5-year prospective randomized study

European Journal of Endocrinology

Volumn 158, Issue 1, 2008, Pages 69-75

  Laurberg, Peter ^a   Wallin, Göran ^b   Tallstedt, Leif ^c   Abraham Nordling, Mirna ^b   Lundell, Göran ^b   Törring, Ove ^d  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ST ERIK S EYE HOSPITAL   (Sweden)

^d Department of Endocrinology and Internal Medicine   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; IODINE 131; LEVOTHYROXINE; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE DRUG DOSE; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; ANTITHYROID AGENTS; AUTOANTIBODIES; AUTOIMMUNITY; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, THYROTROPIN; THYROIDECTOMY; THYROXINE; TIME FACTORS; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 38949133867     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0450     Document Type: Article

References (35)

1. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM & Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy, Clinical Endocrinology 2000 52 267-271.
2. Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J & Morgenthaler NG. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clinical Endocrinology 2004 61 612-618.
3. Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. American Journal of Clinical Dermatology 2005 6 295-309.
4. Pedersen IB, Knudsen N, Perrild H, Ovesen L & Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clinical Endocrinology 2001 55 381-390.
5. Preissner CM, Wolhuter PJ, Sistrunk JW, Homburger HA & Morris JC, III. Comparison of thyrotropin-receptor antibodies measured by four commercially available methods with a bioassay that uses Fisher rat thyroid cells. Clinical Chemistry 2003 49 1402-1404.
6. Davies TF, Ando T, Lin RY, Tomer Y & Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. Journal of Clinical Investigation 2005 115 1972-1983.
7. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R & Carayon P. Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. Journal of Clinical Endocrinology and Metabolism 1988 67 656-662.
8. Pinchera A, Liberti P, Martino E, Fenzi GF, Grasso L, Rovis L, Baschieri L & Doria G. Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. Journal of Clinical Endocrinology and Metabolism 1969 29 231-238.
9. Aizawa Y, Yoshida K, Kaise N, Kaise K, Fukazawa H, Kiso Y, Mori K, Sayama N, Kikuchi K & Abe K. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease. Clinical Endocrinology 1995 42 517-522.
10. Takamura Y, Nakano K, Uruno T, Ito Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K & Miyauchi A. Changes in serum TSH receptor antibody (TRAb) values in patients with Graves' disease after total or subtotal thyroidectomy. Endocrine Journal 2003 50 595-601.
11. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren IG, Blomgren H & Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. New England Journal of Medicine 1992 25 1733-1738.
12. Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M & Hamberger B. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine - a prospective, randomized study. Thyroid Study Group. Journal of Clinical Endocrinology and Metabolism 1996 81 2986-2993.
13. Southgate K, Creagh F, Teece M, Kingswood C & Rees Smith B. A receptor assay for the measurement of TSH receptor antibodies in unextracted serum. Clinical Endocrinology 1984 20 539-548.
14. Morgenthaler NG, Nagata A, Katayama S, Bergmann A & Iitaka M. Detection of low titre TBII in patients with Graves' disease using recombinant human TSH receptor. Clinical Endocrinology 2002 57 193-198.
15. Smith BR, Bolton J, Young S, Collyer A, Weeden A, Bradbury J, Weightman D, Perros P, Sanders J & Furmaniak J. A new assay for thyrotropin receptor autoantibodies. Thyroid 2004 14 830-835.
16. Atkinson S, McGregor AM, Kendall-Taylor P, Peterson MM & Smith BR. Effect of radioiodine on stimulatory activity of Graves' immunoglobulins. Clinical Endocrinology 1982 16 537-543.
17. Teng CS, Yeung RT, Khoo RK & Alagaratnam TT. A prospective study of the changes in thyrotropin binding inhibitory immunoglobulins in Graves' disease treated by subtotal thyroidectomy or radioactive iodine. Journal of Clinical Endocrinology and Metabolism 1980 50 1005-1010.
18. Laurberg R Remission of Graves'disease during anti-thyroid drug therapy Time to reconsider the mechanism? European Journal of Endocrinology 2006 155 783-786.
19. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR & Hall R. Carbimazole and the autoimmune response in Graves' disease. New England Journal of Medicine 1980 7 302-307.
20. Laurberg P, Andersen S & Karmishok J. Anti-thyroid drug therapy of Graves' hyperthyroidism: realistic goals and focus on evidence. Expert Review of Endocrinology and Metabolism 2006 1 91-102.
21. Laurberg P, Nygaard B, Glinoer D, Grussendorf M & Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. European Journal of Endocrinology 1998 139 584-586.
22. Wiersinga WM & Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002 12 855-860.
23. 3 in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. Journal of Clinical Endocrinology and Metabolism 2007 92 2149-2156.
24. 131 I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease. Journal of Clinical Endocrinology and Metabolism 1986 62 773-777.
25. 131 I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study. European Journal of Endocrinology 2004 151 467-474.
26. Kung AW, Yau CC & Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. Journal of Clinical Endocrinology and Metabolism 1994 79 542-546.
27. Bartalena L, Marcocci C, Bogazzi F. Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E & Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. New England Journal of Medicine 1998 8 73-78.
28. Shizume K. Long term antithyroid drug therapy for intractable cases of Graves' disease. Endocrinologia Japonica 1978 25 377-379.
29. Slingerland DW & Burrows BA. Long-term antithyroid treatment in hyperthyroidism. Journal of the American Medical Association 1979 30 2408-2410.
30. Lippe BM, Landaw EM & Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. Journal of Clinical Endocrinology and Metabolism 1987 64 1241-1245.
31. Azizi F, Ataie L, Hedayati M, Mehrabi Y & Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. European Journal of Endocrinology 2005 152 695-701.
32. Cooper DS. Antithyroid drugs. New England Journal of Medicine 2005 3 905-917.
33. Sato K, Yamazaki K, Yamada E, Kanaji Y, Miura M & Obara T. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles. Thyroid 1999 9 979-988.
34. Mukuta T, Tamai H, Oshima A, Morita T, Matsubayashi S, Fukata S & Kuma K. Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH-binding inhibitor immunoglobulin. Clinical Endocrinology 1994 40 215-219.
35. Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita T, Kubo C & Kuma K. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Clinical Endocrinology 1995 43 551-556.